Sign inCreate account

Report workspace

Add to folder
NCT06897527NOT_YET_RECRUITINGanonymous

Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 4

Modality

AI-normalized

small molecule

Target

AI-normalized

Programmed Death-1 (PD-1) receptor

Indication / condition

AI-normalized

Neoplasms, Endometrial

Intervention

Source record

Dostarlimab

Related intelligence directories

Indication directory: NeoplasmsModality directory: small moleculeTarget directory: Programmed Death-1 (PD-1) receptor

Source & freshness

Source record

NCT ID

NCT06897527

Original source

ClinicalTrials.gov

Source last updated

Jul 08, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06897527

Title

Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen

Sponsor

GlaxoSmithKline

Status

NOT_YET_RECRUITING

Phase

Phase 4

Condition raw

Neoplasms, Endometrial

Condition normalized

Neoplasms, Endometrial

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Programmed Death-1 (PD-1) receptor

Target normalized

Programmed Death-1 (PD-1) receptor

Interventions

Dostarlimab

Public preview

Source record

Dostarlimab, a PD-1 inhibitor, is being evaluated for safety in adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer in India. This study addresses a significant unmet need in a population with limited treatment options following platinum-based therapies. The trial's multicenter design may facilitate broader patient recruitment, enhancing GSK's market presence in oncology within the region. Given the increasing prevalence of endometrial cancer and the growing acceptance of immunotherapies, successful outcomes could position GSK favorably against competitors in the PD-1 inhibitor space, particularly in emerging markets. The trial's initiation in mid-2025 aligns with GSK's strategic focus on expanding its oncology portfolio.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT06897527

Status

NOT_YET_RECRUITING

Phase

Phase 4

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Dostarlimab, a PD-1 inhibitor, is being evaluated for safety in adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer in India. This study addresses a significant unmet need in a population with limited treatment options following platinum-based therapies. The trial's multicenter design may facilitate broader patient recruitment, enhancing GSK's market presence in oncology within the region. Given the increasing prevalence of endometrial cancer and the growing acceptance of immunotherapies, successful outcomes could position GSK favorably against competitors in the PD-1 inhibitor space, particularly in emerging markets. The trial's initiation in mid-2025 aligns with GSK's strategic focus on expanding its oncology portfolio.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 08, 2025
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06897527

Indication

Neoplasms, Endometrial

Modality

small molecule

Target

Programmed Death-1 (PD-1) receptor

Intervention

Dostarlimab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.